Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study

Table 4

Hazard ratios for receiving cardiovascular drug treatment from univariable Cox regression and multivariable regularized Cox regression.

	Univariable		Multivariable
	HR (95% CI)	value	HR (95% CI)	value
Men	1.63 (0.94-2.84)	0.083	1.6 (0.91-2.81)	0.103
Age, years	1.04 (1.01-1.07)	0.003	1.04 (1.01-1.07)	0.008
Cholesterol, mmol/L	0.91 (0.73-1.13)	0.391	1	—
LDL-C, mmol/L	0.92 (0.73-1.15)	0.465	1	—
HDL-C, mmol/L	0.87 (0.45-1.69)	0.679	1	—
Triglycerides, mmol/L	0.97 (0.8-1.18)	0.746	1	—
Hypertension	1.21 (0.69-2.13)	0.498	1	—
Former smoker^a	0.8 (0.42-1.52)	0.493	0.71 (0.37-1.37)	0.306
Smoker^a	1.18 (0.58-2.39)	0.654	1.12 (0.53-2.38)	0.761
Diabetes	3.59 (1.83-7.06)	<0.001	3.01 (1.48-6.11)	0.002
Atorvastatin^b	1.72 (0.73-4.01)	0.213	1.64 (0.77-3.48)	0.196
Other statin^b	0.99 (0.22-4.43)	0.987	1	—
Rosuvastatin^b	0.92 (0.29-2.85)	0.879	1	—
Simvastatin^b	0.98 (0.48-2)	0.956	1	—
Medium EQD^c	0.96 (0.53-1.75)	0.9	1	—
High EQD^c	1.24 (0.51-3.01)	0.64	1	—
Low adherence (0-80%)^d	1.29 (0.75-2.25)	0.359	1.18 (0.68-2.07)	0.558

Notes: ^aReference: nonsmoker. ^bReference: stopped using statins/nonpersistent. ^cReference: low EQD (see Table 1). ^dReference: high adherence (80%+). Abbreviations: CI: confidence interval; H(L)DL-C: high- (low-) density lipoprotein cholesterol; HR: hazard ratio.